Skip to main content
رجوع
SHTDF logo

Sinopharm Group Co. Ltd.

جودة البيانات: 100%
ذروة شراء
SHTDF
OTC Healthcare Medical - Distribution
KWD 2.68
▲ KWD 0.05 (1.90%)
القيمة السوقية: 8.35B
مُدرج أيضًا باسم SHTDY OTC
نطاق اليوم
KWD 2.68 KWD 2.68
نطاق 52 أسبوعًا
KWD 2.11 KWD 2.70
حجم التداول
200
متوسط 50 يوم / 200 يوم
KWD 2.47 / KWD 2.37
الإغلاق السابق
KWD 2.63

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 1.2 0.3
P/B 0.1 2.9
ROE % 9.2 3.7
Net Margin % 1.2 3.8
Rev Growth 5Y % 6.4 10.0
D/E 1.0 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2027 KWD 2.442
KWD 2.246 – KWD 2.762
590 B 1
FY2026 KWD 2.391
KWD 2.200 – KWD 2.704
580 B 1

النقاط الرئيسية

Revenue grew 6.38% annually over 5 years — modest growth
Earnings declined -22.14% over the past year
Generating 9.58B in free cash flow
P/E of 1.18 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 8.40%
Cash machine — converts 135.86% of earnings into free cash flow

النمو

Revenue Growth (5Y)
6.38%
Revenue (1Y)-2.02%
Earnings (1Y)-22.14%
FCF Growth (3Y)-28.14%

الجودة

Return on Equity
9.19%
ROIC7.82%
Net Margin1.21%
Op. Margin2.77%

الأمان

Debt / Equity
0.97
Current Ratio1.39
Interest Coverage5.92

التقييم

P/E Ratio
1.18
P/B Ratio0.11
EV/EBITDA1.88
Dividend Yield0.05%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -2.02% Revenue Growth (3Y) 2.89%
Earnings Growth (1Y) -22.14% Earnings Growth (3Y) -9.07%
Revenue Growth (5Y) 6.38% Earnings Growth (5Y) -0.48%
Profitability
Revenue (TTM) 584.51B Net Income (TTM) 7.05B
ROE 9.19% ROA 1.79%
Gross Margin 7.57% Operating Margin 2.77%
Net Margin 1.21% Free Cash Flow (TTM) 9.58B
ROIC 7.82% FCF Growth (3Y) -28.14%
Safety
Debt / Equity 0.97 Current Ratio 1.39
Interest Coverage 5.92 Dividend Yield 0.05%
Valuation
P/E Ratio 1.18 P/B Ratio 0.11
P/S Ratio 0.01 PEG Ratio -0.36
EV/EBITDA 1.88 Dividend Yield 0.05%
Market Cap 8.35B Enterprise Value 30.42B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 584.51B 596.57B 552.15B 521.05B 456.41B
Net Income 7.05B 9.05B 8.53B 7.76B 7.19B
EPS (Diluted) 2.26 2.90 2.73 2.49 2.31
Gross Profit 44.26B 48.51B 47.43B 44.05B 40.32B
Operating Income 16.19B 20.21B 20.60B 19.71B 17.76B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 392.83B 383.39B 364.78B 335.41B 311.24B
Total Liabilities 266.14B 263.08B 254.71B 235.76B 221.29B
Shareholders' Equity 78.88B 74.58B 68.07B 61.89B 56.36B
Total Debt 76.39B 73.78B 69.59B 68.37B 68.53B
Cash & Equivalents 54.31B 63.81B 55.22B 43.53B 50.18B
Current Assets 347.45B 336.84B 319.41B 290.92B 267.61B
Current Liabilities 250.38B 241.49B 234.96B 219.31B 203.98B